| Autor: |
Ganzel, Chezi, Frisch, Avraham, Wolach, Ofir, Moshe, Yakir, Broide, Ellen, Benayoun, Emmanuel, Rowe, Jacob M., Ofran, Yishai |
| Zdroj: |
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2892-2892, 1p |
| Abstrakt: |
Introduction:Liposomal-encapsulated cytarabine and daunorubicin (CPX-351 or Vyxeos) has been approved by the Food and Drug Administration (FDA) for use in the treatment of newly diagnosed therapy-related AML (tAML) and AML with myelodysplasia-related changes (AML-MRCs). This was based on results of a phase III study conducted in patients with secondary AML (Lancet JE et al. JCO 2018). Despite data that highlighted the advantage of CPX-351 for sAML, it is intuitively likely that this powerful drug is also suitable for non-sAML. The mechanism of action is applicable for every AML. The aim of this study is to evaluate the role of CPX-351 for patients with de novolow/ intermediate risk, FLT3-negative AML. While a definitive phase III study is planned, herein is described the pilot forerunner study. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
